This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Schaeybroeck, S. Articles by Longley, D. B. Search for Related Content PubMed PubMed Citation Articles by Van Schaeybroeck, S. Articles by Longley, D. B.

Src and ADAM-17–Mediated Shedding of Transforming Growth Factor- Is a Mechanism of Acute Resistance to TRAIL

Drug Resistance Group, Center for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland

Requests for reprints: Patrick G. Johnston, Center for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland. Phone: 44-2890-972764; Fax: 44-2890-972949; E-mail: oncology{at}qub.ac.uk.

Key Words: TRAIL • Src • ADAM-17 • phospho-EGFR • colorectal cancer

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL/Apo-2L) has emerged as a promising anticancer agent. However, resistance to TRAIL is likely to be a major problem, and sensitization of cancer cells to TRAIL may therefore be an important anticancer strategy. In this study, we examined the effect of the epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) gefitinib and a human epidermal receptor 2 (HER2)–TKI (M578440) on the sensitivity of human colorectal cancer (CRC) cell lines to recombinant human TRAIL (rhTRAIL). A synergistic interaction between rhTRAIL and gefitinib and rhTRAIL and M578440 was observed in both rhTRAIL-sensitive and resistant CRC cells. This synergy correlated with an increase in EGFR and HER2 activation after rhTRAIL treatment. Furthermore, treatment of CRC cells with rhTRAIL resulted in activation of the Src family kinases (SFK). Importantly, we found that rhTRAIL treatment induced shedding of transforming growth factor- (TGF-) that was dependent on SFK activity and the protease ADAM-17. Moreover, this shedding of TGF- was critical for rhTRAIL-induced activation of EGFR. In support of this, SFK inhibitors and small interfering RNAs targeting ADAM-17 and TGF- also sensitized CRC cells to rhTRAIL-mediated apoptosis. Taken together, our findings indicate that both rhTRAIL-sensitive and resistant CRC cells respond to rhTRAIL treatment by activating an EGFR/HER2-mediated survival response and that these cells can be sensitized to rhTRAIL using EGFR/HER2-targeted therapies. Furthermore, this acute response to rhTRAIL is regulated by SFK-mediated and ADAM-17–mediated shedding of TGF-, such that targeting SFKs or inhibiting ADAM-17, in combination with rhTRAIL, may enhance the response of CRC tumors to rhTRAIL. [Cancer Res 2008;68(20):8312–21]

This article has been cited by other articles:

				C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer Experimental Biology and Medicine, July 1, 2009; 234(7): 713 - 725. [Abstract] [Full Text] [PDF]